MARKET

RGNX

RGNX

Regenxbio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

37.05
+1.40
+3.93%
Closed 13:56 11/27 EST
OPEN
35.69
PREV CLOSE
35.65
HIGH
37.12
LOW
34.34
VOLUME
117.98K
TURNOVER
--
52 WEEK HIGH
54.97
52 WEEK LOW
20.03
MARKET CAP
1.39B
P/E (TTM)
-14.9624
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12)
Benzinga · 11/13 12:40
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meeting
REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that two oral presentations will be presented at the American Academy Ophthalmology (AAO) 2020 Annual Meeting, taking place November 13-15, 2020 in a virtual format.
PR Newswire · 11/10 12:00
REGENXBIO to Present at Upcoming Investor Conferences
REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced it will present at the following November investor conferences, which will each be held in a virtual meeting format:
PR Newswire · 11/05 21:05
Regenxbio EPS beats by $1.14, beats on revenue
Regenxbio (RGNX): Q3 GAAP EPS of $0.24 beats by $1.14.Revenue of $98.9M (+572.8% Y/Y) beats by $74.1M.Shares +1.5%.Press Release
Seekingalpha · 11/04 21:10
Investors Who Bought REGENXBIO (NASDAQ:RGNX) Shares Five Years Ago Are Now Up 77%
It hasn't been the best quarter for REGENXBIO Inc. (NASDAQ:RGNX) shareholders, since the share price has fallen 17% in...
Simply Wall St. · 10/27 15:36
Regenxbio earns $80M milestone from Novartis
Regenxbio (RGNX) will receive a milestone payment of $80M from Novartis (NVS) based upon the achievement of $1B in cumulative net sales of Zolgensma. The company expects to recognize this
Seekingalpha · 10/27 12:31
REGENXBIO to Receive $80.0 Million Milestone Payment from Novartis AG
PR Newswire · 10/27 12:00
REGENXBIO To Receive $80.0M Milestone Payment From Novartis AG
ROCKVILLE, Md., Oct. 27, 2020 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its
Benzinga · 10/27 11:20
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RGNX. Analyze the recent business situations of Regenxbio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RGNX stock price target is 57.50 with a high estimate of 100.00 and a low estimate of 31.00.
EPS
Institutional Holdings
Institutions: 264
Institutional Holdings: 29.91M
% Owned: 79.95%
Shares Outstanding: 37.41M
TypeInstitutionsShares
Increased
50
1.42M
New
48
-226.61K
Decreased
63
2.05M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.18%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Director
Allan Fox
President/Chief Executive Officer/Executive Director
Kenneth Mills
Chief Financial Officer/Senior Vice President
Vittal Vasista
Senior Vice President/Chief Technology Officer
Curran Simpson
Senior Vice President/Chief Scientific Officer
Olivier Danos
Senior Vice President
Steve Pakola
Lead Director/Independent Director
A. N. Karabelas
Independent Director
Daniel Abdun-Nabi
Independent Director
Luke Beshar
Independent Director
Alexandra Glucksmann
Independent Director
David Stump
Independent Director
A.N. Karabelas
Independent Director
Daniel Tasse
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Regenxbio Inc stock information, including NASDAQ:RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.